Larger <sup>18</sup>F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

To investigate the relationship between ¹⁸F-fluoroboronotyrosine (FBY) positron emission tomography (PET)- and magnetic resonance imaging (MRI)-defined tumor volumes in contrast-enhanced diffuse gliomas and circumscribed brain tumors.

Methods

A total of 16 diffuse gliomas and 7 circumscribed brain tumors were included, and two types of three-dimensional regions of interest (ROIs), namely, MRI-based ROI (ROI _MRI) and FBY-based ROI (ROI _FBY), were semiautomatically defined. The overlap volume and DICE score were calculated to reveal the spatial relationship between the ROI _MRI and ROI _FBY.

Results

The ROI _MRI was smaller than the ROI _FBY and was mostly contained by the ROI _FBY with an overlap volume of 0.995 ± 0.006 in the whole population. A significant difference in the DICE score was observed between circumscribed tumors and diffuse tumors (0.886 ± 0.026 vs. 0.684 ± 0.165, p = 0.004), and for the regions that have increased FBY metabolism but not MRI contrast enhancement, diffuse tumors and circumscribed tumors showed similar SUVmean values (0.630 ± 0.19 vs. 0.671 ± 0.18, p = 0.625).

Conclusion

FBY uptake beyond contrast enhancement is more significant in diffuse tumors than in circumscribed tumors, which may aid the delineation of active tumor areas and facilitate boron neutron capture therapy.

Related collections

Most cited references 22

Record: found
Abstract: found
Article: found

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Paul Kleihues, Otmar D. Wiestler, Guido Reifenberger … (2016)

The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.

0 comments Cited 3817 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Patrick Wen, David R. Macdonald, David A. Reardon … (2010)

Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas.

0 comments Cited 609 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Primary brain tumours in adults

Arie Perry, Sarah LaPointe, Nicholas A Butowski (2018)

Primary CNS tumours refer to a heterogeneous group of tumours arising from cells within the CNS, and can be benign or malignant. Malignant primary brain tumours remain among the most difficult cancers to treat, with a 5 year overall survival no greater than 35%. The most common malignant primary brain tumours in adults are gliomas. Recent advances in molecular biology have improved understanding of glioma pathogenesis, and several clinically significant genetic alterations have been described. A number of these (IDH, 1p/19q codeletion, H3 Lys27Met, and RELA-fusion) are now combined with histology in the revised 2016 WHO classification of CNS tumours. It is likely that understanding such molecular alterations will contribute to the diagnosis, grading, and treatment of brain tumours. This progress in genomics, along with significant advances in cancer and CNS immunology, has defined a new era in neuro-oncology and holds promise for diagntic and therapeutic improvement. The challenge at present is to translate these advances into effective treatments. Current efforts are focused on developing molecular targeted therapies, immunotherapies, gene therapies, and novel drug-delivery technologies. Results with single-agent therapies have been disappointing so far, and combination therapies seem to be required to achieve a broad and durable antitumour response. Biomarker-targeted clinical trials could improve efficiencies of therapeutic development.

0 comments Cited 489 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Yu Wang: ywang@pumch.cn

Zhi Yang: pekyz@163.com

Zhibo Liu:

ORCID: http://orcid.org/0000-0002-5587-4165

zbliu@pku.edu.cn

Journal

Journal ID (nlm-ta): EJNMMI Res

Journal ID (iso-abbrev): EJNMMI Res

Title: EJNMMI Research

Publisher: Springer Berlin Heidelberg (Berlin/Heidelberg )

ISSN (Electronic): 2191-219X

Publication date (Electronic): 18 April 2022

Publication date PMC-release: 18 April 2022

Publication date Collection: 2022

Volume: 12

Electronic Location Identifier: 22

Affiliations

[1 ]GRID grid.413106.1, ISNI 0000 0000 9889 6335, Department of Neurosurgery, , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, China

[2 ]GRID grid.506261.6, ISNI 0000 0001 0706 7839, Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, , Chinese Academy of Medical Sciences and Peking Union Medical College, ; Beijing, China

[3 ]GRID grid.412474.0, ISNI 0000 0001 0027 0586, Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, , Peking University Cancer Hospital and Institute, ; Beijing, China

[4 ]GRID grid.11135.37, ISNI 0000 0001 2256 9319, Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, , Peking University, ; Beijing, China

[5 ]GRID grid.452723.5, ISNI 0000 0004 7887 9190, Peking University-Tsinghua University Center for Life Sciences, ; Beijing, China

Author information

Zhibo Liu http://orcid.org/0000-0002-5587-4165

Article

Publisher ID: 896

DOI: 10.1186/s13550-022-00896-w

PMC ID: 9016106

PubMed ID: 35435593

SO-VID: 7879c3bf-428a-4e67-b298-10583720f4aa

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 24 January 2022

Date accepted : 10 April 2022

Funding

Funded by: FundRef http://dx.doi.org/10.13039/501100002855, Ministry of Science and Technology of the People's Republic of China;

Award ID: 2021YFA1601400

Award ID: 2017YFA0506300

Award Recipient : Zhibo Liu

Funded by: FundRef http://dx.doi.org/10.13039/501100005089, Beijing Municipal Natural Science Foundation;

Award ID: 7202150

Award ID: Z200018

Award ID: 19JCZDJC64200(Z)

Award Recipient : Wenbin Ma Yu Wang Zhibo Liu

Funded by: FundRef http://dx.doi.org/10.13039/501100002888, Beijing Municipal Commission of Education;

Award ID: 3500-12020123

Award Recipient : Zhibo Liu

Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;

Award ID: U1867209

Award ID: 21778003

Award Recipient : Zhibo Liu

Funded by: FundRef http://dx.doi.org/10.13039/501100007937, Peking University;

Award ID: LGZNQN202004

Award Recipient : Zhibo Liu

Funded by: FundRef http://dx.doi.org/10.13039/501100004147, Tsinghua University;

Award ID: 2019ZLH101

Award Recipient : Wenbin Ma

Custom metadata

ScienceOpen disciplines: Radiology & Imaging

Keywords: fluoroboronotyrosine,pet,brain tumor,diffuse glioma,metastasis,volume comparison,boron neutron capture therapy

Data availability:

ScienceOpen disciplines: Radiology & Imaging

Keywords: fluoroboronotyrosine, pet, brain tumor, diffuse glioma, metastasis, volume comparison, boron neutron capture therapy